Regeneron Pharmaceuticals, Inc. v. Amgen Inc.

  1. April 11, 2025

    Amgen Can't Ditch Regeneron's Bundling Antitrust Suit

    A Delaware federal judge on Thursday denied Amgen's bid to toss antitrust litigation brought by Regeneron accusing its rival of using a bundling scheme to increase the sales of its cholesterol drug Repatha and push competitors out of the market.

  2. March 30, 2023

    Off Beat: Funding, Face-Offs & Food Fights

    A Texas federal judge who does significant patent work will be stepping down, drug companies sparring over patents at the U.S. Supreme Court found themselves again going toe-to-toe over a different area of law, California judges provided trial tips throughout March, and the integrity of popular snacks was brought into question in Illinois. Here's what intellectual property attorneys should know about these issues and others outside their practice.

  3. March 21, 2023

    Amgen Must Face Regeneron's Bundling Antitrust Suit

    Amgen can't escape a lawsuit accusing it of using a bundling scheme to increase the sales of its cholesterol drug Repatha and push competitors out of the market, a Delaware federal judge has ruled.

  4. February 13, 2023

    Court Told Not To Toss Regeneron's Amgen Bundling Suit

    A magistrate judge recommended a Delaware federal court deny Amgen's attempts to toss or delay Regeneron's claims that Amgen Inc. used a bundling scheme to boost its cholesterol medication sales and said additional documents Amgen submitted should be ignored.

  5. August 09, 2022

    Amgen Looks To Duck Regeneron's Bundling Suit

    Pharmaceutical giant Amgen asked a Delaware federal court to throw out a suit from competitor Regeneron alleging that Amgen used a bundling scheme to boost its own cholesterol medication sales while ruining the market for Regeneron's competing product.

  6. May 31, 2022

    Regeneron Rips Amgen's 'Bundling Scheme' Amid IP Feud

    Regeneron Pharmaceuticals Inc. has launched a new antitrust lawsuit accusing Amgen of an illegal "bundling scheme" aimed at destroying the market for Regeneron's cholesterol medication Praluent and boosting sales of its main rival product, Amgen's Repatha.